Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ruxolitinib · Jakafi, Jakafi Xr

Small molecule · Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) · developed by Incyte

Approved FDA, Nov 2011
INCY Developer
4 Registered trials

What is Ruxolitinib?

Ruxolitinib is a kinase inhibitor that blocks JAK1 and JAK2, which mediate signaling of cytokines and growth factors involved in hematopoiesis and immune function. It is studied in graft-versus-host disease, vitiligo, myelofibrosis, chronic myelomonocytic leukemia, and pyoderma gangrenosum.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Jakafi, Jakafi Xr, Opzelura, INCB-018424, INCB-18424, INC-424, Jakafi, INCB018424
Drug type
Small molecule
Targets
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2)
Mechanism
Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2)
Pathways
JAK-STAT signaling, cytokine signaling, hematopoiesis, inflammatory cytokine production
Therapy area
Dermatology, Immunology, Oncology
Developer
Incyte Corp (INCY)
FDA status
Approved as Jakafi, Jakafi Xr, Opzelura (November 16, 2011), NDA202192 · FDA label
UNII
82S8X8XX8H

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06804811 Phase 3 NonSegmental Vitiligo Recruiting INCY
NCT06615050 Phase 3 Graft-versus-host Disease (GVHD) Recruiting INCY
NCT07783412 Phase 2 Pyoderma Gangrenosum Recruiting INCY
NCT07128381 Phase 1/2 Myelofibrosis (MF) Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Myelomonocytic Leukemia (CMML)Graft-versus-host Disease (GVHD)Myelofibrosis (MF)NonSegmental VitiligoPyoderma Gangrenosum

Other drugs acting on JAK1 / JAK2

More from Incyte

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Ruxolitinib

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.